Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proglumetacin SCHEMBL28086382 | 1.00 | PTGS2 (0.55) | PTGS2PTGS1BCL2L1 | |
| Proglumetacin SCHEMBL27106 | 0.97 | PTGS2 (0.59) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL29384391 | 0.97 | PTGS2 (0.59) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL99165 | 0.94 | PTGS2 (0.56) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL19642980 | 0.94 | PTGS2 (0.56) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL1650599 | 0.94 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL5077578 | 0.88 | PTGS2 (0.57) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL4094289 | 0.88 | PTGS2 (0.52) | PTGS2 | |
| Proglumetacin SCHEMBL13724384 | 0.88 | PTGS2 (0.49) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL5482765 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-7906646-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100280058-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100222374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100120808-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7638527-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1235561-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | Panacea Biotec Limited (IN) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001039749-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | PANACEA BIOTEC LIMITED (IN) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | PTGS2 397/4885PTGS1 325/4885BCL2L1 4265/4885 |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | PTGS2 397/4885PTGS1 325/4885BCL2L1 4265/4885 |
| US-20100280058-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | PTGS2 397/4885PTGS1 325/4885BCL2L1 4265/4885 |
| US-20100120808-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | PTGS2 397/4885PTGS1 325/4885BCL2L1 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.